Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer (March 15, 2024) | By Tyler Patchen, BioSpace. Swedish-based gene therapy biotech Asgard Therapeutics has closed a €30 million ($32.6 million) Series A to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology, the company announced Thursday. The funding round was led by
Novartis Pays $90M for Molecules That Could Take STING Out of Inflammation Placing research in the hands of a large pharmaceutical company is a goal of many biotech companies. IFM Therapeutics has now done it three times and its latest deal is the second time Novartis is the acquirer. (March 13, 2024) | By Frank
Summary – Ever wondered how delving into the uncharted territory of microbes could reshape healthcare? This episode is a treasure trove of insights for anyone looking to bridge the gap between complex scientific research and practical investor appeal.
